Thiopurine S-methyltransferase deficiency
Dernière mise à jour 17 Jul 2023
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
Thiopurine S-methyltransferase (TPMT) deficiency is a condition characterised by significantly reduced activity of an enzyme that helps the body process drugs called thiopurines. These drugs, which include 6-thioguanine, 6-mercaptopurine, and azathioprine, inhibit (suppress) the body's immune system. Thiopurine drugs are used to treat some autoimmune disorders, including Crohn's disease and rheumatoid arthritis, which occur when the immune system malfunctions. These drugs are also used to treat several forms of cancer, particularly cancers of blood-forming tissue (leukemias) and cancers of immune system cells (lymphomas). Additionally, thiopurine drugs are used in organ transplant recipients to help prevent the immune system from attacking the transplanted organ.
Sélections vidéo pour Conditions génétiquesBibliothèque vidéo
Description
Thiopurine S-methyltransferase (TPMT) deficiency is a condition characterised by significantly reduced activity of an enzyme that helps the body process drugs called thiopurines. These drugs, which include 6-thioguanine, 6-mercaptopurine, and azathioprine, inhibit (suppress) the body's immune system. Thiopurine drugs are used to treat some autoimmune disorders, including Crohn's disease and rheumatoid arthritis, which occur when the immune system malfunctions. These drugs are also used to treat several forms of cancer, particularly cancers of blood-forming tissue (leukemias) and cancers of immune system cells (lymphomas). Additionally, thiopurine drugs are used in organ transplant recipients to help prevent the immune system from attacking the transplanted organ.
A potential complication of treatment with thiopurine drugs is damage to the bone marrow (hematopoietic toxicity). Although this complication can occur in anyone who takes these drugs, people with TPMT deficiency are at highest risk. Bone marrow normally makes several types of blood cells, including red blood cells, which carry oxygen; white blood cells, which help protect the body from infection; and platelets, which are involved in blood clotting. Damage to the bone marrow results in myelosuppression, a condition in which the bone marrow is unable to make enough of these cells. A shortage of red blood cells (anaemia) can cause pale skin (pallor), weakness, shortness of breath, and extreme tiredness (fatigue). Low numbers of white blood cells (neutropenia) can lead to frequent and potentially life-threatening infections. A shortage of platelets (thrombocytopenia) can cause easy bruising and bleeding.
Many healthcare providers recommend that patients' TPMT activity levels be tested before thiopurine drugs are prescribed. In people who are found to have reduced enzyme activity, the drugs may be given at a significantly lower dose or different medications can be used to reduce the risk of hematopoietic toxicity.
TPMT deficiency does not appear to cause any health problems other than those associated with thiopurine drug treatment.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal codominant. More than one pattern can apply in different cases.
Related genes
Other names
Poor metabolism of thiopurines
Thiopurine methyltransferase deficiency
TPMT deficiency
Related patient information and medicines

Patient information leaflet
Puis-je prendre le complexe de vitamine B et la vitamine C ensemble ?
It is best to take your vitamins with water rather than tea or coffee. Using other medicines Taking multiple medicines. Our Medicines Interaction Checker helps vous check whether votre prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.

Patient information leaflet
Malabsorption gastro-intestinale
Gastrointestinal malabsorption syndrome means a failure to fully absorb digested foods from the gut (bowel) into your body. There are many different causes. Prolonged intestinal malabsorption may cause problems because of a lack of carbohydrates, proteins, fats, minerals and vitamins that are essential to keep you healthy. The treatment will.

Patient information leaflet
Puis-je prendre le cohosh noir et l'acide folique ensemble ?
Why this happens Black cohosh and folic acid are processed by the body through different pathways. Black cohosh is primarily broken down by liver enzymes (specifically le CYP450 system), while de l'acide folique is a water-soluble B vitamin that follows a separate metabolic route. They do not interfere with each other's absorption or effectiveness. Our.

Patient information leaflet
Genoux cagneux
Occasionally - in either older children or adults - there can be an underlying problem causing the cond... For example: Vitamin deficiency (particularly vitamin D deficiency causing rickets Vitamin D deficiency ). Vitamin C Vitamin C deficiency and calcium deficiency can also affect the way bones grow. Rheumatoid arthritis Rheumatoid arthritis or.

Patient information leaflet
Puis-je prendre de la vitamine B12 et de la vitamine C ensemble ?
Using other medicines Taking multiple medicines. Our Vérificateur d'Interactions Médicamenteuses helps you check whether votre prescriptions, over-the-counter medicines, et supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do about them. Disclaimer This information is for general educational.

Patient information leaflet
Puis-je prendre de la vitamine C et de la vitamine D ensemble ?
Taking it on an empty stomach may reduce its effectiveness. Using other medicines Taking multiple medicines. Our Vérificateur d'Interactions Médicamenteuses helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do about them..
Lectures complémentaires et références
- Thiopurine S-methyltransferase deficiency; MedlinePlus, National Library of Medicine.
- Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998 Nov 1;129(9):716-8. doi: 10.7326/0003-4819-129-9-199811010-00007.
- Cooper SC, Ford LT, Berg JD, Lewis MJ. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics. 2008 Mar;9(3):303-9. doi: 10.2217/14622416.9.3.303.
- Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs. 2005 Dec;23(6):523-32. doi: 10.1007/s10637-005-4020-8.
- Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 Apr 15;19(8):2293-301. doi: 10.1200/JCO.2001.19.8.2293.
- Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010 May 1;79(9):1211-20. doi: 10.1016/j.bcp.2010.01.006. Epub 2010 Jan 21.
- Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014 Apr;77(4):704-14. doi: 10.1111/bcp.12226.
- Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.
- Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002 Aug;12(6):429-36. doi: 10.1097/00008571-200208000-00003.
- Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005 Mar 23;293(12):1485-9. doi: 10.1001/jama.293.12.1485.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

